ISN and AstraZeneca India join hands this World Kidney Day to fulfil the theme of ‘Kidney Health for All’
Kolkata:This World Kidney Day, Indian Society of Nephrology (ISN), the largest professional organization of nephrologists in India dedicated to advancing kidney health worldwide and AstraZeneca, a science-led biopharmaceutical company, announced a multi-year partnership to create public awareness about kidney care and related health disorders, build education at primary care physician level on early diagnosis, prompt management and aid nationwide screening for at risk patients and general public to promote timely detectionand holistic management.
Chronic Kidney Disease (CKD) today has become a major cause of global mortality and morbidity. In India, the most common cause of CKD is diabetic nephropathy. Studies estimate that the number of patients diagnosed with End Stage Kidney Disease (ESKD) in India, who are either on dialysis or scheduled for transplantation is over 100,000 per year. It is also estimated that 9 out of 10 patients may not even know that they suffer from a kidney ailment.
Under this year’s theme of ‘Kidney Health For All’, ISN along with AstraZeneca aims to generate large scale awareness and educate people about ways to improve kidney health. As a part of this partnership, AstraZeneca under close guidance from ISN will facilitate ‘Project SEARCH’-a mass screening program for early diagnosis of CKD in diabetic or hypertensive patients who are at high risk of kidney damage. This campaign will be conducted at over 2000 physician clinics over a period of one month atmultiple locations across the country and is expected to reach out to 2.4 lac patients. The society has nominated top nephrologists of the country as regional coordinators to provide the requisite scientific support and mentorship to participating physicians.
ISN will also spearhead the analysis of the collected data that can be used to change the practice and influence policy makers. Dr AK Bhalla President-Indian Society of nephrology and Chairman, Department of Nephrology at Sir Gangaram Hospital, New Delhisaid“As per the India Chronic Kidney Disease registry results that were published recently by our group, there is a 38% increase in the proportion of deaths attributable to kidney failure between 2001–03 and 2010–13. This alarming statistic shows that there is a gap in the awareness, early identification and management of the disease. The Indian Society of Nephrology has been constantly working towards increasing the awareness levels among the general public about kidney related diseases as well as providing support to physicians through trainings and diagnostic support. And we feel that this partnership with AstraZeneca will enhance our efforts towards better kidney care in India”.
To bring down the overall burden of kidney diseases on our health systems, this partnership will also focus upon undertaking certificate programs by country’s top 30 nephrologists for about 1000 primary care physicians through three interactive modules. These will point towards deep education on key signs for early diagnosis, awareness and management strategies and relevant point of interventions. Dr. Arpita Ray Chaudhury: Vice President-Indian Society of Nephrology; Professor, Department of Nephrology, IPGMER & SSKM Hospital, Kolkata added,“World Kidney Day (WKD) is a global campaign aimed at raising awareness of the importance of our kidneys. Increasing prevalence of diabetes and hypertension across the globe has also given rise to increasing incidence of chronic kidney disease. Chronic kidney disease (CKD) is common and harmful: 1 out of 10 adult people worldwide have it, and if left untreated it can be deadly. Early detection allows for disease care and management, and prevents morbidity and mortality, so improving kidney health literacy may decrease short- and long-term adverse outcomes. So, in 2022, the world kidney slogan is bridging the knowledge gap to better kidney care”.
Speaking on this occasion, Dr. Anil Kukreja, VP- Regulatory and Medical Affairs, AstraZeneca India, said “Chronic Kidney Disease in simple terms means that kidney do not work at their full capacity which if ignored can lead to renal complications and sometimes failure. Our partnership with ISN is a firm step towards collaboratively reducing CKD related mortality and morbidity rate through patient & HCP education and improving kidney health for all. Under the aegis of ISN, we will be able to impart right education amongst public so that they understand that early detection is really crucial to slow down progression to improve long term health outcomes”.
Lastly, these activities will be complemented by a robust social media presence in form of Facebook live awareness sessions by prominent nephrologists on various aspects of CKD, which is expected to impart knowledge to millions of community members at large. This session will be available for public to log in and connect with these experts from 7pm-8pm everyday between March 14 to March 22 at facebook.com/BeyondSugarIN
About AstraZeneca Pharma India Limited: AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas -Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. AstraZeneca Pharma India Limited (AZPIL) was established in 1979 and mark edits 40th year of a long-standing commitment to patients in India. It is headquartered at Bengaluru, Karnataka. AstraZeneca
